In this report we describe a cytotoxic T-cell epitope in the Epstein-Barr virus nuclear antigen EBNA 6. This epitope is present on both A-and B-type transformants.
Epstein-Barr virus (EBV) is harbored for life in association with B lymphocytes in all previously infected individuals (10) . In vitro, the proliferation of these EBV-infected B lymphocytes is controlled by CD4 and CD8 cytotoxic T lymphocytes (CTLs) specifically activated to recognize a functionally defined lymphocyte-detected membrane antigen (8, 13) . Two types of EBV (A and B) are recognized that show DNA sequence divergence within the BAM Hi WYH and E regions of the EBV genome (la) and encode a family of EBV nuclear antigens, EBNAs 2, 3, 4, and 6 and EBNA-LP, which are expressed in all latently infected EBV-transformed cell lines. An alternative nomenclature also in current use designates the EBNA family as EBNAs 2, 3a, 3b, and 3c and EBNA-LP (3, 5, 6, 12) . Allelic polymorphism between A and B types of EBV has now been implied for each of the above EBNA antigens (16, 17) .
We recently defined the first EBV-coded sequence capable of acting as a target for EBV-specific lysis (1).This sequence is coded by a genome region that is divergent between A-and B-type EBV. In the present report we describe for the first time an EBV peptide sequence that is encoded by both A-and B-type EBV and is capable of acting as a target for CTL lysis.
EBV-transformed cell lines were established either spontaneously (14) (i.e., by transformation with endogenous virus) or by the addition of exogenous virus (9) . Exogenous EBV was prepared from three A-type cell lines, IARC-BL36 (17), IARC-BL74 (19) , and B95-8 (7) (referred to as B95), and from the B-type cell lines Ag876 (la), L19, L4, and JS (17) . EBV CTL clones (9) and interleukin-2-dependent PHA blast cell lines (Burrows et al., in press) were generated from a seropositive donor designated DM (HLA AW24, 29; BW44, 47), and PHA blasts were also established from a range of other donors. The following exemplify the cell line designations used throughout. The EBV-transformed cells from donor DM transformed with virus from IARC-BL36 is referred to as DM\BL36; similarly the spontaneous cell line from donor DM was referred to as DM\spon; PHA blasts from donor DM are designated DM\PHA.
To identify the CTL epitope recognised by EBV-specific CTL clones from donor DM, a series of peptides from EBNA 2, 3, 4, and 6 was synthesized (20 to 25 amino acids) (4) by using the known sequence of the B95 strain of EBV. In all, 39 peptides from EBNA 2, 7 peptides from EBNA 3, 6 peptides from EBNA 4, and 6 peptides from EBNA 6 were tested. Peptides selected were primarily those that corresponded to predicted algorithms (2, 15) . Peptides were * Corresponding author. dissolved in RPMI 1640 and distributed into U-well microdilution plates (200 jig/ml, 20 ,ul per well) and frozen at -70°C until required. 51Cr-labeled PHA blasts from donor DM were added to each well (2 x 105/ml, 50 RI per well) and incubated at 37°C. After 1 h, 130 ,ul of cloned autologous CTLs from donor DM were added to the reaction mixture (final effector to target ratio as indicated), and the assay was conducted as previously described (Burrows et al., in press).
Six EBV-specific CTL clones were isolated from donor DM. All clones were CD3+, CD8+, and CD4-and recognized the three autologous A-type transformants and the three autologous B-type transformants (these clones are referred to as cross-reactive CTL clones). The data presented in Fig. 1 refer to results obtained with clone 3, but these are essentially identical to those recorded with other CTL clones from donor DM.
To define the restricting major histocompatibility complex allele recognized by clone 3, a series of autologous and HLA-related and -unrelated allogeneic targets was used (Fig. 2) . The results suggest that this T-cell clone recognized a virus-coded epitope in the context of BW44, although not all BW44 targets were recognized. This result reinforces previous data showing heterogeneity at this allele (11) .
EBV peptides from EBNAs 2, 3, 4, and 6 were screened for their ability to act as targets for EBV-specific CTL lysis after adsorption onto autologous PHA blasts. Of the 58 peptides screened, only 1 (peptide 77) had a significant effect on the lysis of autologous PHA blasts (Fig. 3) . The sequence of this peptide, which was derived from the EBNA 6 (EBNA 3c) protein (encoded by bases 99285 through 99344), is EENLLDFVRFMGVMSSCNNP (open reading frame BERF4, residues 290 through 309). This result was confirmed with all six CTL clones by using three separate syntheses of peptide 77. Titration experiments showed that peptide 77 was 50% active when incubated with targets at 1 ,ug/ml.
Two cold target competition experiments were conducted. In the first experiment (Fig. 4A) The present results demonstrate that EBV-specific CTL clones recognize an EBV peptide sequence on autologous Aand B-type LCLs and on autologous PHA blasts exposed to the specific peptide. It can therefore be inferred that this epitope is encoded by both A-and B-type viruses. It is relevant to point out that comparison between the sequence of peptide 77 and the corresponding B-type sequence (J. Sample et al., unpublished data) reveals homology at the amino acid level between the two types from residues 290 through 307.
The presence of a CTL epitope in the EBNA 6 protein is reminiscent of the published data on other viruses, where nuclear proteins frequently include CTL epitopes (18) I   I   I  I  I  I  I  I  I  I  I  I   I  I 
